For patients with autoimmune disease, higher baseline B-cell counts and systemic inflammation are associated with development of cytokine release syndrome (CRS) after chimeric antigen receptor (CAR) T-cell therapy, according to a study published in the November issue of The Lancet Rheumatology.
❓ Unknown
Biomarkers for Risk of Cytokine Release Syndrome After CAR T-Cell Therapy Identified
Just now
October 26, 2026
1 min read
📰 Medical Xpress
📋 Key Takeaway
A study published in The Lancet Rheumatology identifies that patients with autoimmune diseases who have higher baseline B-cell counts and systemic inflammation are at increased risk of developing cytokine release syndrome after CAR T-cell therapy. This research is significant for the medical community in Iran as it may influence treatment protocols for autoimmune diseases. Understanding these biomarkers could improve patient outcomes in Iranian healthcare settings.
🏷️ Entities Mentioned
🌐
Translated from the original and edited for English readers. View original source →
Translation confidence: 100%
📰 Related Coverage
Just now •
Three Executed in Isfahan: A Woman for Murder and Two Men for Drug Offenses
13 min ago •
How Shoes Influence Bone Structure and Human Evolution
13 min ago •
Immunotherapy Combination Significantly Improves Survival for Small Cell Lung Cancer Patients
13 min ago •
The Importance of Urban Green Spaces for Biodiversity Conservation
22 min ago •